(Immuno)proteasomes as therapeutic target in acute leukemia

Jacqueline Cloos; Margot S.F. Roeten; Niels E. Franke; Johan van Meerloo; Sonja Zweegman; Gertjan J.L. Kaspers; Gerrit Jansen

doi:https://doi.org/10.1007/s10555-017-9699-4

(Immuno)proteasomes as therapeutic target in acute leukemia

Jacqueline Cloos, Margot S.F. Roeten, Niels E. Franke, Johan van Meerloo, Sonja Zweegman, Gertjan J.L. Kaspers, Gerrit Jansen

Research output: Contribution to journal › Article › Academic › peer-review

27 Citations (Scopus)

Abstract

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress.

Original language	English
Pages (from-to)	1-17
Number of pages	17
Journal	Cancer and Metastasis Reviews
DOIs	https://doi.org/10.1007/s10555-017-9699-4
Publication status	Published - Dec 2017

Keywords

Constitutive proteasome
Drug resistance
Immunoproteasome
Leukemia
Proteasome inhibition

Access to Document

https://doi.org/10.1007/s10555-017-9699-4

Cite this

@article{871c6e8e8e2a4d4cad9d52a2edf0f7d6,

title = "(Immuno)proteasomes as therapeutic target in acute leukemia",

abstract = "The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress.",

keywords = "Constitutive proteasome, Drug resistance, Immunoproteasome, Leukemia, Proteasome inhibition",

author = "Jacqueline Cloos and Roeten, {Margot S.F.} and Franke, {Niels E.} and {van Meerloo}, Johan and Sonja Zweegman and Kaspers, {Gertjan J.L.} and Gerrit Jansen",

year = "2017",

month = dec,

doi = "https://doi.org/10.1007/s10555-017-9699-4",

language = "English",

pages = "1--17",

journal = "Cancer and Metastasis Reviews",

issn = "0167-7659",

publisher = "Springer Netherlands",

}

TY - JOUR

T1 - (Immuno)proteasomes as therapeutic target in acute leukemia

AU - Cloos, Jacqueline

AU - Roeten, Margot S.F.

AU - Franke, Niels E.

AU - van Meerloo, Johan

AU - Zweegman, Sonja

AU - Kaspers, Gertjan J.L.

AU - Jansen, Gerrit

PY - 2017/12

Y1 - 2017/12

N2 - The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress.

AB - The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress.

KW - Constitutive proteasome

KW - Drug resistance

KW - Immunoproteasome

KW - Leukemia

KW - Proteasome inhibition

UR - http://www.scopus.com/inward/record.url?scp=85032187130&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s10555-017-9699-4

DO - https://doi.org/10.1007/s10555-017-9699-4

M3 - Article

C2 - 29071527

SN - 0167-7659

SP - 1

EP - 17

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

ER -

(Immuno)proteasomes as therapeutic target in acute leukemia

Abstract

Keywords

Access to Document

Other files and links

Cite this